secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-092213
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Pharmaceuticals appoints Jonathan M. Poole to Board of Directors
-----------------------------------------------------------------------

- Poole appointed effective March 3, 2026 as Class II director, term expiring at 2027 annual meeting.
- He will serve on the Audit Committee; receives $50k annual cash retainer plus $12.5k for committee role.
- Initial equity grant with $200k target fair value (split options/RSUs); prorated annual grant of $95,300.
- Future annual equity grants of $400k (half options, half RSUs) with quarterly vesting over one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526092213/0001193125-26-092213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526092213/acad-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-092213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer